As Pfizer kills failed PhIII programs for Bavencio, where do they go from here in R&D?

As Pfizer kills failed PhIII programs for Bavencio, where do they go from here in R&D?

Source: 
Endpoints
News Tags: 
snippet: 

Pfizer managed to disappoint just about everyone this morning with its full-year outlook as generic competition eats into their big franchise revenue streams. For a company that has long prided itself on the numbers, it was a telling setback that follows a wide-ranging reorganization plan that is culling staff and eliminating segments of R&D.